Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IBIO-600

Other · developed by iBio

Phase 1 Most advanced trial

IBIO Developer

1 Registered trials

What is IBIO-600?

IBIO-600 is an investigational drug studied in Overweight , Obesity.

At a glance

Drug type: Other
Therapy area: Metabolic
Developer: iBio, Inc. (IBIO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07487376	Phase 1	Overweight , Obesity	Recruiting	IBIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Overweight , Obesity

Sources

ClinicalTrials.gov NCT07487376

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBIO page.

Follow IBIO, the company behind IBIO-600

See IBIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBIO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z